These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 26638268)

  • 41. Prophylaxis against venous thromboembolism in acutely ill medical patients: an observational study.
    Peterman CM; Kolansky DM; Spinler SA
    Pharmacotherapy; 2006 Aug; 26(8):1086-90. PubMed ID: 16863485
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and economic outcomes with appropriate or partial prophylaxis.
    Amin AN; Lin J; Johnson BH; Schulman KL
    Thromb Res; 2010 Jun; 125(6):513-7. PubMed ID: 19931121
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Venous thromboembolism prophylaxis after total hip arthroplasty].
    Kučera T; Malý R; Urban K; Sponer P
    Acta Chir Orthop Traumatol Cech; 2011; 78(2):101-5. PubMed ID: 21575551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
    Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
    N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved use of thromboprophylaxis for deep vein thrombosis following an educational intervention.
    Cohn SL; Adekile A; Mahabir V
    J Hosp Med; 2006 Nov; 1(6):331-8. PubMed ID: 17219525
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
    Amin AN; Lin J; Lenhart G; Schulman KL
    Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk factors for inpatient venous thromboembolism despite thromboprophylaxis.
    Wang TF; Wong CA; Milligan PE; Thoelke MS; Woeltje KF; Gage BF
    Thromb Res; 2014 Jan; 133(1):25-9. PubMed ID: 24300584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Venous thromboembolism prophylaxis for the general surgical patient: where do we stand?
    Petralia GA; Kakkar AK
    Semin Respir Crit Care Med; 2008 Feb; 29(1):83-9. PubMed ID: 18302090
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study.
    Hamad GG; Choban PS
    Obes Surg; 2005; 15(10):1368-74. PubMed ID: 16354513
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dosing of enoxaparin for venous thromboembolism prophylaxis in obese patients.
    Willett KC; Alsharhan M; Durand C; Cooper MR
    Ann Pharmacother; 2013 Dec; 47(12):1717-20. PubMed ID: 24301685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment patterns of venous thromboembolism in a real-world population: the Q-VTE study cohort.
    Tagalakis V; Patenaude V; Kahn SR; Suissa S
    Thromb Res; 2014 Oct; 134(4):795-802. PubMed ID: 25135794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevention of venous thromboembolism amongst patients in an acute tertiary referral teaching public hospital: a best practice implementation project.
    Sykes PK; Walsh K; Darcey CM; Hawkins HL; McKenzie DS; Prasad R; Thomas A
    Int J Evid Based Healthc; 2016 Jun; 14(2):64-73. PubMed ID: 27167767
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Venous thromboembolism risk and thromboprophylaxis among hospitalized patients: data from the Turkish arm of the ENDORSE study.
    Ongen G; Yılmaz A; Cirak AK; Ersoy CY; Erden F; Altıntaş F; Yıldırım C; Güven H; Demir A; Kaynar L; Bastacı N; Demirtaş N
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):539-45. PubMed ID: 20829272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lessons from French National Guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients.
    Farge D; Durant C; Villiers S; Long A; Mahr A; Marty M; Debourdeau P;
    Thromb Res; 2010 Apr; 125 Suppl 2():S108-16. PubMed ID: 20433988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anticoagulant use in real time.
    Srinivasan D; Watzak B
    J Pharm Pract; 2013 Jun; 26(3):270-9. PubMed ID: 23178414
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
    Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
    Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Venous thromboembolism in elderly high-risk medical patients: time course of events and influence of risk factors.
    Hull RD; Merali T; Mills A; Stevenson AL; Liang J
    Clin Appl Thromb Hemost; 2013; 19(4):357-62. PubMed ID: 23610237
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Improving inpatient venous thromboembolism prophylaxis.
    Shedd GC; Franklin C; Schumacher AM; Green DE
    South Med J; 2008 Dec; 101(12):1209-15. PubMed ID: 19005426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Venous thromboembolism risk assessment and prophylaxis in hospitalised medical patients in the Cape Town metropole, South Africa.
    Wehmeyer A; Coetzee R; McCartney J
    S Afr Med J; 2022 Feb; 112(2):13506. PubMed ID: 35139994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.